Giedre Krenciute

发表

Analysis of the Human Endogenous Coregulator Complexome

D. Chan, B. Kim, A. Malovannaya, 2011, Cell.

T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges

Dalia Haydar, Giedre Krenciute, Jorge Ibañez-Vega, 2021, Frontiers in Oncology.

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells

Shondra M. Pruett-Miller, Dalia Haydar, P. Nguyen, 2020, Molecular therapy oncolytics.

CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy

Sheng Zhou, Giedre Krenciute, J. Condori, 2020, Cancers.

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

S. Gottschalk, Giedre Krenciute, Brooke Prinzing, 2018, Expert review of anticancer therapy.

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

Hao Liu, I. Balyasnikova, M. Lesniak, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

P. Nguyen, S. Gottschalk, D. Spencer, 2017, Cancer discovery.

Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation

Maureen A. McGargill, Dalia Haydar, M. McGargill, 2021, Cell reports.

IL-12 signaling promotes TET2-mediated DNA demethylation during CD8 T cell effector differentiation

Maureen A. McGargill, Dalia Haydar, M. McGargill, 2020, bioRxiv.

Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.

M. Roussel, T. Shaw, S. Baker, 2020, Neuro-oncology.

cBAF complex components and MYC cooperate early in CD8+ T cell fate

Shondra M. Pruett-Miller, D. Green, Piyush Sharma, 2022, Nature.

Nuclear BAG6-UBL4A-GET4 Complex Mediates DNA Damage Signaling and Cell Death*

B. Kim, M. Leng, J. Qin, 2013, The Journal of Biological Chemistry.

RASA2 ablation in T cells boosts antigen sensitivity and long-term function

Ansuman T. Satpathy, A. Marson, Eric Shifrut, 2022, Nature.

Augmenting CAR NK cell Anti-tumor Activity by Synapse Tuning

S. Gottschalk, P. Chockley, Giedre Krenciute, 2022, bioRxiv.

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

S. Riddell, G. Dotti, Giedre Krenciute, 2022, Nature reviews. Clinical oncology.

Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies

J. Orange, M. Brenner, Giedre Krenciute, 2017, Cancer Immunology Research.

Synapse-tuned CARs enhance immune cell anti-tumor activity

S. Gottschalk, P. Chockley, Giedre Krenciute, 2023, Nature Biotechnology.

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

Hao Liu, I. Balyasnikova, S. Gottschalk, 2017, Cancer Immunology Research.

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

S. Gottschalk, Giedre Krenciute, Felicia Cao, 2018, Molecular therapy. Methods & clinical development.

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Shannon K. Boi, Shondra M. Pruett-Miller, S. Tsai, 2021, Science Translational Medicine.

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight

Dalia Haydar, P. Musich, Giedre Krenciute, 2020, Journal of Translational Medicine.

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.

J. Orange, C. Rooney, J. Cabral, 2017, Cell reports.

De novo DNA methylation programs regulate CAR T-cell exhaustion

S. Tsai, J. Crawford, Dalia Haydar, 2020, The Journal of Immunology.

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma

Giedre Krenciute, Christopher T. Petersen, G. Krenciute, 2019, Front. Oncol..

CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity

Ruochi Zhang, Yang Yang, Samantha Maragh, 2020, Nature Biotechnology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

MyD88/CD40 signaling retains CAR T cells in a less differentiated state

Yiping Fan, P. Schreiner, S. Gottschalk, 2020, JCI insight.

Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies

J. Klco, C. Mullighan, J. Crawford, 2022, Blood.

Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?

Giedre Krenciute, Brooke Prinzing, G. Krenciute, 2021, Cell reports. Medicine.

CD47 expression is critical for CAR T-cell survival in vivo

Shondra M. Pruett-Miller, P. Vogel, S. Gottschalk, 2023, Journal for ImmunoTherapy of Cancer.

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.

I. Balyasnikova, M. Lesniak, S. Gottschalk, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity

S. Tsai, Yong Cheng, Ruochi Zhang, 2020, Nature Biotechnology.

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling

Besian I. Sejdiu, H. Chi, Hao Shi, 2023, Nature biomedical engineering.

IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors

Giedre Krenciute, Heather W. Sheppard, Elizabeth Wickman, 2024, Journal for immunotherapy of cancer.